Epetraborole + Epetraborole + Placebo + Placebo

Phase 2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Mycobacterium Abscessus Infection

Conditions

Mycobacterium Abscessus Infection

Trial Timeline

Mar 1, 2026 → Dec 1, 2027

NCT ID

NCT07301320

About Epetraborole + Epetraborole + Placebo + Placebo

Epetraborole + Epetraborole + Placebo + Placebo is a phase 2 stage product being developed by AN2 Therapeutics for Mycobacterium Abscessus Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07301320. Target conditions include Mycobacterium Abscessus Infection.

What happened to similar drugs?

3 of 8 similar drugs in Mycobacterium Abscessus Infection were approved

Approved (3) Terminated (1) Active (4)

✅clarithromycin, rifabutinPfizerApproved

✅AzithromycinPfizerApproved

✅Azithromycin + Rifabutin/rifampinPfizerApproved

🔄Ethambutol hydrochloride + Clarithromycin + AzithromycinPfizerPhase 3

🔄ALIS + Azithromycin + Ethambutol + ELCInsmedPhase 3

🔄ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)InsmedPhase 3

🔄LAI (Liposomal Amikacin for Inhalation) 590 mgInsmedPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07301320	Phase 2	Recruiting	Mar 1, 2026	Dec 1, 2027	Mycobacterium Abscessus Infection

Competing Products

20 competing products in Mycobacterium Abscessus Infection

See all competitors

Product	Company	Stage	Hype Score
Trifluridine	Amgen	Pre-clinical	26
clarithromycin, rifabutin	Pfizer	Approved	43
Azithromycin	Pfizer	Pre-clinical	26
Ethambutol hydrochloride + Clarithromycin + Azithromycin	Pfizer	Phase 3	40
Azithromycin	Pfizer	Pre-clinical	26
Azithromycin	Pfizer	Pre-clinical	26
Azithromycin	Pfizer	Pre-clinical	26
Azithromycin	Pfizer	Approved	43
Tigecycline	Pfizer	Phase 2	35
Azithromycin + Rifabutin/rifampin	Pfizer	Approved	43
ALIS + Azithromycin + Ethambutol + ELC	Insmed	Phase 3	37
ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)	Insmed	Phase 3	37
LAI plus multi-drug regimen	Insmed	Phase 2	32
Liposomal amikacin for inhalation (LAI) + placebo	Insmed	Phase 2	32
LAI (Liposomal Amikacin for Inhalation) 590 mg	Insmed	Phase 3	37
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Ceftriaxone for Injection + Amoxicillin + Azithromcyin + clarithromycin + Clofazimine + Ethambutol + Amikacin Injection + tigecycline + Imipenem + Cilastatin + Cefoxitin + Amikacin (Inhalation) + linezolid + Trimethoprim / Sulfamethoxazole + Doxycycline + moxifloxacin + bedaquiline + Rifabutin	Innoviva	Phase 2	36
Molgramostim nebulizer solution	Savara	Phase 2	21
Inhaled molgramostim + Antimycobacterial regimen	Savara	Phase 2	29
SPR720 + Placebo + Open-label Standard of Care	Spero Therapeutics	Phase 2	17
RHB-204 + Placebo	RedHill Biopharma	Phase 3	22